PainReform Ltd
PRFX
Get informed when a big investor buys or sells
+ FollowMarket Cap$80.3K
Close$
$6.42
545% upside
Current Fair Value
545% upsideUndervalued by 545% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $80,298.00 |
|---|---|
| Enterprise Value | $-3,023,702.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-7.47 |
| Beta | 1.04 |
| Outstanding Shares | 647,973 |
Return
| Return on Equity | -56.63% |
|---|---|
| Return on Assets | -40.32% |
| Return on Invested Capital | -53.59% |
Valuation & Multiples
| P/E Ratio | -0.03 |
|---|---|
| PEG | -0.06 |
| Price to Sales | - |
| Price to Book Ratio | 0.07 |
| Enterprise Value to Revenue | -177.86 |
| Enterprise Value to EBIT | 0.59 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -0.01 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
July 2, 2026
EPS Estimate
$-612.00
Average shareholder expectationRevenue Estimate
$14,722
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 1.81%▲ 1.81% |
|---|---|
| Total Invested | $31,939 |
| Investors Holding | 4▲ 4.00% |
ESG Score
No data
About PainReform Ltd
2 employeesPainReform is a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics. PRF-110, the Company's lead product, is based on the local anesthetic ropivacaine, targeting the post-operative pai...